Paper Information

Title: 

CYTOGENETIC EFFECTS OF GONADOTROPIN RELEASING HORMONE ANALOGUE: BUSERELIN DURING OVULATION INDUCTION CYCLE BY SISTER-CHROMATID EXCHANGE ASSAY

Type: POSTER
Author(s): RAHIMIAN M.*,GOURABI H.,MAADANI T.,BEHJATI F.
 
 *DEPARTMENT OF BIOLOGY, SCHOOL OF BASIC SCIENCE AND RESEARCH BRANCH, ISLAMIC AZAD UNIVERSITY, POONAK, TEHRAN, IRAN
 
Name of Seminar: IRANIAN CONGRESS OF PHYSIOLOGY AND PHARMACOLOGY
Type of Seminar:  CONGRESS
Sponsor:  PHYSIOLOGY AND PHARMACOLOGY SOCIETY, MASHHAD UNIVERSITY OF MEDICAL SCIENCE
Date:  2009Volume 19
 
 
Abstract: 

Increasing use of assisted reproductive technologies (ART), make the investigation on its complications more necessary. One of the main concerns in this regard is the side effects of medications required for controlled ovarian stimulation. Systemic and local reactions to the medications, ovarian hyper stimulation syndrome (OHSS) and genetic changes which can lead to cancer must be checked in treatment of infertile patients. In this study, cytogenetic effect of Buserelin, which is a gonadotropin hormone agonist (GnRH agonist), has been evaluated during Invitro Fertilization Cycle (IVF). Blood samples were taken from 60 females referring to Royan institute (30 females in ART cycle use that have Buserelin from day 15 to day 2 of second menstrual cycle and 30 normal fertile women as control), cultured and examined by sister chromatid exchange (SCE) assay, considered as the most sensitive system for measuring the effects of mutagenic carcinogens in mammalian. Also the changes of 17-β-estradiol (E2), which is known to produce adverse effects such as embroyotoxicity, teratogenicity and carcinogenicity by DNA damaging, were evaluated in days 15 and 2 of menstrual cycles of both patient and control groups. In both groups, evaluation of SCE frequencies demonstrates lower rate around early follicular phase as compared to ovulation time, because of lower dosage of E2. More declines in SCE frequency was observed after Buserelin injection because of its inhibitory effect on E2, which results in the greater decrease in E2 dosage. Finally, results of this study indicate that Buserelin doesn’t seem to have a significant potential for induction of malignancies after ovulation induction treatment, and other medications used in ovulation stimulation must be evaluated as well.

 
Keyword(s): BUSERELIN, IN-VITRO FERTILIZATION CYCLE, 17-β-ESTRADIOL, SISTER CHROMATID EXCHANGE
 
Yearly Visit 16   tarjomyar
 
Latest on Blog
Enter SID Blog